Hope for reducing the cardiovascular complications associated with dialysis

Biotech companies Invizius and 3P Biopharmaceuticals collaborate on an innovative technology for patients undergoing hemodialysis and suffering from cardiovascular disease. Invizius, a Scottish biotech company and 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, have initiated a collaboration on an innovative treatment for reducing […]

FESTIVAL OF BIOLOGICS (2 – 6 November 2020)

Festival of Biologics 2020

We are looking forward to participating in FESTIVAL OF BIOLOGICS delivered virtually on 2-6 November 2020. Schedule a partnering meeting with us to learn how we can boost your biologics projects. 5 days covering Antibodies, Immunotherapy, Biosimilars and solutions for pharma and biotech. Are you looking for a CDMO? Let’s talk!

3P Biopharmaceuticals and SpyBiotech enter into a vaccine contract manufacturing agreement

3P Biopharmaceuticals and SpyBIotech agreement

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement withSpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. Oxford, UK-based SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of […]

BIO EUROPE 2020 (October, 26–29)

We are looking forward to participating in BIO EUROPE 2020 delivered digitally on October, 26–29. Schedule a partnering meeting with us to learn how we can boost your biologics projects.

3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

Professional with extensive experience in biotechnology companies 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics appoints a new member to the management team with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director. José Luis Bartolomé has a solid […]

3P Biopharmaceuticals appoints Iker Portugal as Chief Financial Officer

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics incorporates a new member to the management team and appoints Iker Portugal as Chief Financial Officer. Iker Portugal is an experienced financial manager and joins 3P Biopharmaceuticals with the aim of boosting the company´s growth […]

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedish Biotech company, have initiated a collaboration on innovative treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG). 3P Biopharmaceuticals and Toleranziabegan their partnership in 2019, when 3P Biopharmaceuticals was selected to […]

3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

CIR certificate is extended for a four-year period between 2020-2024 3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024. The CIR ”Credit Impôt Recherche” or French Research Tax Credit is a corporate […]

STATEMENT: 3P Biopharmaceuticals shows its commitment against Covid-19

We are living in difficult times due to the COVID19 pandemic, and it is in these times of serious difficulty that 3P Biopharmaceuticals shows its maximum commitment to its employees and to society. Therefore, 3P Biopharmaceuticals makes its capabilities and knowledge available to the Spanish Health Authorities as well as companies in the pharmaceutical and […]

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use. 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and Viscofan BioEngineering, the Business Unit within the Viscofan Group), go one step further in an innovative cell therapy product. […]